Target intelligence / Profile preview

Beta-cell damage

Molecular classification
Other
01

Overview

Beta-cell damage" refers to the loss of function or viability of pancreatic beta cells, which are responsible for insulin production in the islets of Langerhans. This damage can result from autoimmune attack (Type 1 diabetes), metabolic stress (Type 2 diabetes), or exposure to inflammatory cytokines, oxidative stress, or toxic metabolites. The major biochemical mechanisms include apoptosis, necroptosis, autophagy, and sometimes pyroptosis, usually driven by cytokine signaling (e.g., IL-1β, TNFα, IFNγ), oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction, and DNA damage. Loss of beta-cell mass or identity (dedifferentiation) is a hallmark of diabetes pathogenesis, leading to hyperglycemia and loss of glucose homeostasis[1][2][3][4][5][6][7]. Summary: "Beta-cell damage" is a description of a cell injury/dysfunction process, not a discrete molecular target such as a receptor or enzyme. Therefore, it does not fit as a "therapeutic target" in the typical sense and is an incorrect entry for target-based structured databases.

Other names
Beta cellPancreatic beta cellβ-cellBeta-cell dysfunctionBeta-cell apoptosisBeta-cell loss
02

Biological functions

Insulin secretionGlucose regulationCell death (when referring to damage)
03

Disease associations

Diabetes (Type 1, Type 2)Other metabolic diseases
04

Safety considerations

Loss of endogenous insulin production (leads to hyperglycemia, risk of ketoacidosis)Hypoglycemia (in advanced type 2 diabetes due to loss of insulin modulation)
05

Biomarkers

Insulin levelsC-peptide levelsCirculating autoantibodies (islet cell antibodies, GAD65 antibodies)

Beyond the preview

Go deeper on Beta-cell damage.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-cell damage.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call